Company news
ProQR Therapeutics N.V. news in 2023
ProQR Therapeutics N.V.'s news releases, calls and decks from 2023, newest first.
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 7, 2023
ProQR Announces Third Quarter 2023 Operating and Financial Results
November 6, 2023
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 5, 2023
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 27, 2023
ProQR Therapeutics Provides Update on Ophthalmic Assets
September 26, 2023
ProQR Announces Second Quarter 2023 Operating and Financial Results
August 2, 2023
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
July 31, 2023
ProQR Announces First Quarter 2023 Operating and Financial Results
May 15, 2023
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 17, 2023
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 28, 2023
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
March 13, 2023
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 27, 2023